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Introduction: Pulmonary spindle cell carcinoma (SpCC) is a rare subtype of non-small-cell lung cancer
(NSCLC) and, in general, is chemoresistance.
Case: A sixty-ﬁve year-old male patient with metastatic pulmonary SpCC was initially treated with
cisplatin and docetaxel, but his disease progressed. Then, he received a combination chemotherapy with
carboplatin and nab-PTX followed by maintenanced chemotherapy with nab-PTX. Fluorodeoxyglucose
(FDG) positron-emission CT revealed a substantial decrease of FDG accumulation in the primary tumor,
and the response continued for more than 7 months.
Discussion: Preclinical models suggested that nab-PTX may reach the tumor microenvironment more
efﬁciently than solvent-based paclitaxel (sb-PTX) and be preferentially taken up by cancer cells.
Considering that there is no effective treatment for patients with pulmonary SpCC, nab-PTX may merit
further investigation in patients with pulmonary SpCC.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Pulmonary sarcomatoid carcinoma (PSC) is deﬁned as a poorly
differentiated non-small-cell lung cancer (NSCLC) containing sar-
coma or a sarcoma-like component. Pulmonary spindle cell carci-
noma (SpCC) is a rare subgroup of PSC comprised only of spindle
cells. In general, SpCC is chemoresistance, and a few cases with
poor outcome have been reported in an advanced stage.
Nanoparticle albumin-bound paclitaxel (nab-PTX) is an
albumin-bound, 130 nm particle form of paclitaxel that exhibits a
higher activity and lower toxicity than solvent-based paclitaxel (sb-
PTX). In a previous phase III study comparing nab-PTX with sb-PTX
in combination with cabboplatin, nab-PTX demonstratedMedicine, Graduate School of
o, Sakyo-ku, Kyoto 606-8507,
).
Ltd. This is an open access article usigniﬁcantly better response rate and less neuropathy than sb-PTX
in advanced NSCLC [1].
Here, we described a case of pulmonary SpCC, refractory to
cisplatin plus docetaxel, but which responded to subsequent
treatment with carboplatin plus nab-PTX.
Case
A 65-year-old never-smoking male presented with progressing
right hypochondrial pain. Contrast-enhanced computed tomogra-
phy (CT) revealed a 74-mm irregular tumor in the right lower lobe
with diaphragm invasion (Fig. 1A). Fluorodeoxyglucose (FDG)
positron-emission CT demonstrated marked FDG accumulation in
the marginal region of the lung tumor and solitary nodule-shaped
accumulations in pleura, liver, and the right gluteal muscles
(Fig. 2A and C).
Ultrasound-guided needle biopsy of the nodule in the gluteal
muscle was performed to avoid an unnecessary biopsy because
massive necrosis was suspected in the lung tumor. Histologically,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Imaging ﬁndings in chest computed tomography (CT). (A) Contrast-enhanced CT showing a 74-mm irregular tumor in the right lower lobe with diaphragm invasion. (B) Plane
CT showing a 111-mm tumor after 1 cycle of cisplatin plus docetaxel treatment. (C) Contrast-enhanced CT showing an 83-mm tumor after 2 cycles of carboplatin with albumin-
bound paclitaxel.
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invasion to skeletal muscles and clustered necrotic foci (Fig. 3A).
Neither tubular formation nor squamous differentiation was
identiﬁed.
Immunohistochemical analysis demonstrated that the tumor
cells were diffusely positive for cytokeratin AE1/AE3 and vimentin
(Fig. 3B), and negative for S-100, p63, synaptophysin, and thyroid
transcription factor 1 (TTF-1). The patient was diagnosed with
spindle cell carcinoma (SpCC) of the lung based on the World
Health Organization (WHO) criteria.1 The clinical stage was IV
(cT4N1M1b).
First-line chemotherapy with cisplatin and docetaxel was
started, but disease progression (Fig. 1B) and grade 2 creatinine
elevation were observed after 1 cycle. Subsequently, chemo-
therapy with carboplatin and nab-PTX was started. CT taken after
2 cycles of chemotherapy demonstrated a reduction of tumor size
(Fig. 1C), and FDG-PET revealed a substantial decrease of FDG
accumulation in the primary tumor (Fig. 2B). The patient received
4 cycles of the combination therapy followed by 4 cycles of
continued maintenance therapy with nab-PTX, and is now alive 9
months from the diagnosis with the maintenance of stable disease
for 7 months.Fig. 2. Fluorodeoxyglucose (FDG) positron-emission computed tomography ﬁndings at diag
marginal region of the lung tumor and low accumulation in the center of the tumor. (B) L
paclitaxel. (C) Nodule-shaped accumulation in left gluteal muscles at diagnosis.Discussion
In the current WHO histological classiﬁcation of lung tumors,
PSC is deﬁned as a poorly differentiated NSCLC containing sarcoma
or a sarcoma-like component. Pulmonary SpCC is a subgroup of PSC
comprised only of spindle cells [2]. In terms of advanced or recur-
rent pulmonary SpCC, a few cases have been reported, with a poor
outcome [3,4]. To our knowledge, this is the ﬁrst case of successful
treatment of pulmonary SpCC at an advanced stage.
A retrospective cohort of 97 patients with advanced or recurrent
PSC receiving conventional chemotherapy showed better
progression-free survival (PFS) in some patients receiving a plat-
inum plus gemcitabine or sb-PTX regimen, although most patients
presented a poor outcome (median PFS: 2.0 months) [5]. As
described in this report, interestingly, nab-PTX was effective in a
patient refractory to docetaxel.
Although sb-PTX has often been selected for the treatment of
PSC, nab-PTX must take the place of sb-PTX in future considering
that nab-PTX has obvious superiority in both efﬁcacy and toxicity in
patients with NSCLC [1]. Preclinical models suggested that nab-PTX
may reach the tumor microenvironment more efﬁciently than sb-
PTX and be preferentially taken up by cancer cells [6].nosis and at 8 weeks after treatment initiation. (A) Marked accumulation of FDG in a
ow accumulation in the lung tumor after 2 cycles of carboplatin with albumin-bound
Fig. 3. Histopathological ﬁndings of the nodule obtained from left gluteal muscle. (A) Low-power (left) and high-power (right) images of a hematoxylin and eosin-stained section
showing the tumor comprised only of spindle-shaped malignant cells with clustered necrotic regions (white arrow) and invasion to skeletal muscles (black arrow). (B) Immu-
nohistochemical analysis showing diffuse cytokeratin AE1/AE3 (left) and vimentin (right) positivity.
T. Tsuji et al. / Respiratory Medicine Case Reports 15 (2015) 48e5050As a limitation to this work, we could not completely demon-
strate that the whole tumor was comprised only of spindle cells,
since the obtained sample was just a part of the whole tumor. In
previous reports, however, an SpCC diagnosis was described as
being given based on biopsy samples [3,4].
In conclusion, we have presented a case of PSC, probably pul-
monary SpCC, refractory to cisplatin plus docetaxel, but which
responded to subsequent treatment with carboplatin plus nab-PTX.
Considering that there is no effective treatment for patients with
PSC, including pulmonary SpCC, nab-PTX may merit further
investigation in this rare but extremely aggressive disease.
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